A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Compared to another common class of kidney medications, called DPP4is, GLP1-RA medications did better in helping slow the progression of kidney disease, keeping kidney disease patients out of the ...

GLP-1 is a hormone made naturally in the gut. It plays a big role in managing blood sugar and appetite while releasing ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

CagriSema combines the GLP-1 receptor agonist (GLP-1RA) semaglutide, used in blockbuster weight-loss drug Wegovy, with dual ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...